5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit 2026

Achieving precise extrahepatic delivery remains one of the biggest challenges in the LNP field. However, with AbbVie’s acquisition of Capstan Therapeutics and BMS’s acquisition of Orbital Therapeutics, the industry’s confidence in targeted LNPs has never been higher!
 
Returning to Boston in June 2026, the 5th Extrahepatic Lipid-Based Nanoparticles Delivery Summit is bringing together industry pioneers and leading delivery experts to showcase the latest advances in novel targeting ligands and innovative lipid-based technologies. Across 3 jam-packed days, attendees will gain in-depth technical insights into accelerating the delivery of mRNA, RNA, gene-editing, and cell therapy payloads to extrahepatic tissues, including immune cells, adipose tissues, muscle, and more.
 
With world-class speakers from the likes of AbbVie, AstraZeneca, Novartis, Mote Therapeutics, Strand Therapeutics, and more, this is your premium opportunity to stay at the cutting-edge of extrahepatic targeting as well as collectively overcome challenges in targeted LNP analytics, scalability, and immunogenicity. Join this expert-led forum dedicated solely to delivery outside the liver and accelerate cell-specific LNPs towards the clinic.